Related Experiment Video
Updated: Jun 20, 2026
05:52
Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
Published on: May 12, 2023
Prolonged acquired neutropenia in children
Jiunn-Ming Sheen1, Ho-Chang Kuo, Hong-Ren Yu
1Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung, Taiwan.
Pediatric Blood & Cancer
|August 28, 2009
Summary
Younger age, thrombocytosis, and cytomegalovirus (CMV) infection are risk factors for prolonged acquired neutropenia in children. Infants with CMV infection may benefit from antiviral therapy to shorten neutropenia duration.
Area of Science:
- Pediatrics
- Hematology
- Infectious Diseases
Background:
- Acquired neutropenia is a common condition in childhood.
- Identifying risk factors for prolonged neutropenia is crucial for effective management.
Purpose of the Study:
- To investigate risk factors associated with prolonged acquired neutropenia in pediatric patients.
- To identify predictors of persistent neutropenia beyond three months.
Main Methods:
- Retrospective review of 66,062 hospital admissions from 2002-2006.
- Inclusion of 735 admissions with acquired neutropenia after excluding specific conditions.
- Multivariate logistic regression and Kaplan-Meier analysis were used.
Main Results:
- An absolute neutrophil count <500/mm(3), thrombocytosis, and age <1 year were significant predictors of prolonged neutropenia.
- Cytomegalovirus (CMV) infection was associated with more prolonged neutropenia compared to influenza or Epstein-Barr virus.
- Among patients with follow-up, 26 out of 252 remained neutropenic after 3 months, with 14 recovering after 1 year.
Conclusions:
- Younger age, thrombocytosis, and CMV infection are key factors associated with prolonged acquired neutropenia.
- Neutropenic infants with CMV infection may require prompt antiviral treatment.
- Early identification of these risk factors can guide clinical decisions and potentially shorten neutropenia duration.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:25Immunodeficiency Diseases
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
There are three main causes of immunodeficiency disorders...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:22Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...